Theralase Annual General Meeting
Toronto, Ontario--(Newsfile Corp. - June 5, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ('Theralase®" or the 'Company'), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is reminding shareholders of its Annual General and Special Meeting ('AGSM') to take place on Wednesday, June 11 th, 2025 at 4:30 pm ET at the Company's head office located at 41 Hollinger Road, Toronto, Ontario, Canada.
In order to help make the AGSM more interactive for those shareholders, who are unable to attend in person, immediately after the formal part of the AGSM has concluded, Theralase® will be hosting a virtual presentation at 5:15 pm ET, which will include a corporate presentation of the Company's strategic objectives for 2025 and 2026, as well as a question and answer period to provide an opportunity for shareholders to have their questions addressed.
The corporate power point presentation and question and answer period will end at 6:30 pm ET.
Zoom Meeting Link: https://us02web.zoom.us/j/87175139183
Webinar ID: 871 7513 9183
Conference Call in: 1-647-558-0588 (Canada) / 1-646-558-8656 (US) - not required for those attending by Zoom.
An archived version will be available on the website, the next business day, following the conference call.
About Theralase® Technologies Inc.:
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue.
Additional information is available at www.theralase.com and www.sedarplus.ca
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains Forward-Looking Statements ('FLS') within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words 'may, 'should', 'will', 'anticipates', 'believes', 'plans', 'expects', 'estimate', 'potential for' and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals.
These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.
Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS.
Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS.
All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS.
For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies.
For More Information:
1.866.THE.LASE (843-5273)
416.699.LASE (5273)
www.theralase.com
Kristina Hachey, CPA
Chief Financial Officer X 224
[email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254481
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNET
3 hours ago
- CNET
AT&T Has a New Affordable Senior Mobile Plan -- and Sorry, 55 Counts as a 'Senior'
AT&T has revealed its new phone plan for seniors, which offers mobile service at a discount for customers 55 years old and up. (Yes, Gen X, that's you -- or some of you, at least.) While the new plan only has the essentials, it's also cheaper than the carrier's feature-packed options. Even better, it's notably more affordable than AT&T's former senior plan. Carriers typically offer several plans to satisfy a range of customers, from the frugal to those that are willing to pay for every perk and bundled streaming service they can get. But plans targeting older Americans are often more bare-bones offerings, offered at lower prices to appeal to customers on fixed and limited incomes. AT&T's new AT&T 55 Plus plan is the most affordable it's offered in years. In exchange, the AT&T 55 Plus plan is pretty basic. For $40 per month for a single line (or $35 per month per line with two lines), you'll get unlimited voice calls, texting and data in the US, Canada and Mexico, and though AT&T's senior plan page indicates it has "5G access included," there's no clarity on which circumstances will enable high-speed data downloads and uploads on the senior plan. The plan also has 10GB of hotspot data per line per month, which is more generous than some other carrier offerings on our best senior plans list, along with a maximum 720p (SD) streaming speed for video. The plan also provides access to AT&T's free ActiveArmor app that blocks spam calls. Previously, AT&T offered a slightly discounted senior phone plan at $62 per month that was only available to customers living in Florida. Verizon retains a similar Florida-only senior plan. T-Mobile has several plans for seniors, from an older and basic Essentials Choice 55 plan starting at $45 per month up to Experience Beyond w/ 55 Plus starting at $85 per month and offering all the perks and extras of T-Mobile's other plans, including a five-year plan price guarantee, streaming services and satellite service beyond T-Mobile's network. Here's a breakdown of the best senior plans carriers offer 55-years-old and up customers: Best Senior Plans: T-Mobile, AT&T, Mint Mobile and Verizon Plan Cost 1 line (AutoPay) Cost 4 lines (AutoPay) High-speed data Hotspot data limit Price guarantee Max number of lines Streaming resolution T-Mobile Essentials Choice 55 $45 N/A 50GB Unlimited 3G N/A 2 480p (SD) T-Mobile Go5G 55 Plus $75 N/A Unlimited 5G 50GB N/A 2 Up to 4K T-Mobile Experience Beyond w/ 55+ $85 N/A Unlimited 5G 250GB 5 years 2 Up to 4K AT&T AT&T 55+ $40 $140 Unlimited 10GB N/A 10 480p (SD) Mint Mobile Mint 55 $15 N/A 5GB Shared 5GB main data budget N/A 5 480p (SD) Verizon Verizon 55 Plus $62 N/A Unlimited 4G LTE Unlimited 3G N/A 2 480p (SD) It's worth noting that every carrier plan's listed lowest price requires customers to sign up for autopay -- otherwise, the plans are more expensive every month. Customers must also prove their age by submitting an identification document to their carrier. Later this summer, AT&T will also offer a bundle combining two lines of AT&T 55+ with the customer's choice of either AT&T Fiber or AT&T Internet Air fixed wireless access internet, according to the carrier's blog post.
Associated Press
4 hours ago
- Associated Press
Oncoscope Officially Launches, Ushering in a New Era of Real Time Oncology Intelligence
06/06/2025, Miami, Florida // PRODIGY: Feature Story // Anna Forsythe, founder of Oncoscope-AI (source: Oncoscope-AI) Oncoscope-AI, a revolutionary oncology intelligence platform, has officially launched following a successful beta phase and over a year of strategic development that involved extensive conversations with practicing oncologists. The platform, which delivers real-time, human-curated cancer insights enhanced by artificial intelligence, is now live and available free of charge to verified healthcare professionals worldwide. Founded by Anna Forsythe, a pharmacist, health economist, and seasoned pharmaceutical executive, Oncoscope addresses a critical gap in oncology care. It gives clinicians instant access to the most current treatment data, FDA approvals, and guideline-aligned information, consolidated into one user-friendly platform. 'Doctors do not need more data. They need the right information, at the right time, in a format they can use to make better decisions for their patients,' said Forsythe. 'Oncoscope provides that clarity. It is a living library of oncology, curated by experts and built to save lives.' Unlike generic AI tools or static databases, Oncoscope uses trained AI to scan thousands of oncology publications and filters them through a rigorous, evidence-based framework. Each entry is cross-referenced with clinical guidelines and regulatory approvals to ensure usability and relevance. All of the results are carefully scrutinized by a team of experienced researchers. Currently, the platform supports breast and lung cancer, with prostate, bladder, colon, and rectal modules rolling out in the coming months. The process is intuitive. Physicians answer three clinical questions—cancer stage, genetic markers, and prior treatments—and receive a personalized, actionable summary. Each recommended article includes survival data, progression insights, treatment efficacy, and toxicity, extracted across 32 key clinical parameters. 'The result is something physicians can actually use in the moment,' said Forsythe. 'It takes three clicks to go from a patient in the room to the most up-to-date evidence in the field.' Access to Oncoscope is free for verified healthcare professionals, including physicians, nurses, pharmacists, genetic counselors, and physician assistants. Non-verified users, such as those in finance or consulting, can purchase limited access at a monthly rate, restricted to a single cancer type. This structure reflects the company's commitment to empowering front-line clinicians with better tools—without barriers. Forsythe, who previously founded and sold a successful health economics company serving global pharmaceutical clients, brings a rare combination of clinical, technical, and business expertise to this venture. She sees Oncoscope not only as a tool, but as a mission. 'This platform was born from both professional insight and personal urgency,' she said. 'Too many patients are still receiving outdated treatments, simply because their doctors do not have time to stay current. I realized I had the knowledge, the team, and the experience to fix that.' With a lean team, strategic vision, and a rapidly growing user base, Oncoscope is poised to become a trusted global resource in cancer treatment. 'We are not just a tech company,' said Forsythe. 'We are part of the oncology ecosystem. And we are here to help doctors deliver the best care possible.' For more information, visit Media Contact: Name - Anna Forsythe Email - [email protected] Source published by Submit Press Release >> Oncoscope Officially Launches, Ushering in a New Era of Real Time Oncology Intelligence
Associated Press
4 hours ago
- Associated Press
Electric Metals Announces Termination of Agreement With Terrella Capital
TORONTO, ON / ACCESS Newswire / June 6, 2025 / Electric Metals (USA) Limited ('EML' or the 'Company') (TSXV:EML)(OTCQB:EMUSF) announces that the Company and Terrella Capital Ltd. ('Terrella') have mutually agreed to terminate their business consulting services agreement, originally announced on April 15, 2025. The agreement was formally terminated effective May 27, 2025. In connection with the termination, the 250,000 stock options previously contemplated for grant to Terrella under the agreement have been cancelled and will not be issued. About Electric Metals (USA) Limited Electric Metals (USA) Limited (TSXV: EML) (OTCQB: EMUSF) is a US-based mineral development company with manganese and silver projects geared to supporting the transition to clean energy. The Company's principal asset is the Emily Manganese Project in Minnesota, the highest-grade manganese deposit in North America, which has been the subject of considerable technical studies, including National Instrument 43-101 Technical Reports - Resource Estimates. The Company's mission in Minnesota is to become a domestic US producer of high-value, high-purity manganese metal and chemical products to supply the North American electric vehicle battery, technology and industrial markets. With manganese playing a critical and prominent role in lithium-ion battery formulations, and with no current domestic supply or active mines for manganese in North America, the development of the Emily Manganese Project represents a significant opportunity for America, the State of Minnesota and for the Company's shareholders. For further information, please contact: Electric Metals (USA) Limited Brian Savage CEO & Director (303) 656-9197 or Valerie Kimball Director Investor Relations 720-933-1150 [email protected] Forward-Looking Information This news release contains 'forward-looking information' and 'forward-looking statements' (collectively, 'forward-looking information') within the meaning of applicable securities laws. Forward-looking information is generally identifiable by use of the words 'believes,' 'may,' 'plans,' 'will,' 'anticipates,' 'intends,' 'could', 'estimates', 'expects', 'forecasts', 'projects' and similar expressions, and the negative of such expressions. Such statements in this news release include, without limitation: the ability of the Company to complete the Offering; the size, terms and timing of the Offering; participation in the Offering by insiders of the Company; the timing and receipt of TSXV and other approvals required in connection with the Offering; the intended use of proceeds of the Offering; the Company's mission to become a domestic US producer of high-value, high-purity manganese metal and chemical products to supply the North American electric vehicle battery, technology and industrial markets; that manganese will continue to play a critical and prominent role in lithium-ion battery formulations; that with no current domestic supply or active mines for manganese in North America, the development of the Emily Manganese Project represents a significant opportunity for America, Minnesota and for the Company's shareholders; and planned or potential developments in ongoing work by Electric Metals. These statements address future events and conditions and so involve inherent risks, uncertainties and other factors that could cause actual events or results to differ materially from estimated or anticipated events or results implied or expressed in such forward-looking statements. Such risks include, but are not limited to, the failure to obtain all necessary stock exchange and regulatory approvals; investor interest in participating in the Offering; and risks related to the exploration and other plans of the Company. Forward-looking information is based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and perception of trends, updated conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances at the date such statements are made. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events, or developments, except as required by law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE: Electric Metals (USA) Limited press release
